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ABSTRACT		1 
Objectives	2 
To determine the relationship between synovial versus skin transcriptional/histological profiles in 3 
patients with active psoriatic arthritis (PsA) and explore mechanistic links between diseased tissue 4 
pathology and clinical outcomes.  5 
Methods	6 
Twenty-seven active PsA patients were enrolled in an observational/open-label study and underwent 7 
biopsies of synovium and paired lesional/non-lesional skin before starting anti-TNF (if biologic-naïve) 8 
or ustekinumab (if anti-TNF inadequate responders). Molecular analysis of 80-inflammation-related 9 
genes and protein levels for IL-23p40/IL-23p19/IL-23R were assessed by real-time-PCR and 10 
immunohistochemistry, respectively. 11 
Results	12 
At baseline, all patients had persistent active disease as per inclusion criteria. At primary end-point 13 
(16-weeks-post-treatment), skin responses favoured ustekinumab, while joint responses favoured 14 
anti-TNF therapies. Principal-component-analysis revealed distinct clustering of synovial tissue gene 15 
expression away from the matched-skin. While IL12B-IL23A-IL23R were homogeneously expressed in 16 
lesional skin, their expression was extremely heterogeneous in paired synovial tissues. Here, IL-23 17 
transcriptomic/protein expression was strongly linked to patients with high-grade synovitis who, 18 
however, were not distinguishable by conventional clinimetric measures. 19 
Conclusions	20 
PsA synovial tissue shows a heterogeneous IL-23 axis profile when compared to matched skin. Synovial 21 
molecular-pathology may help to identify among clinically indistinguishable patients those with a 22 
greater probability of responding to IL-23 inhibitors.  23 
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INTRODUCTION	1 
Psoriatic arthritis (PsA) is a chronic heterogeneous inflammatory condition occurring in up to 30% of 2 
patients with skin and/or nail psoriasis (PsO), which variably affects the spine, peripheral synovial joints 3 
and entheses.[1] Although the mechanisms for such disease heterogeneity are not entirely clear, the 4 
interleukin (IL)-23/IL-17 axis is believed to be key in PsO and PsA pathogenesis.[2,3]  5 
IL-23 is a proinflammatory cytokine composed of two subunits (p40, in common with IL-12, and p19, 6 
IL-23-specific) and mostly produced by keratinocytes, dendritic and myeloid cells. By binding its 7 
cognate receptors (IL-23R/IL-12Rβ1), it stabilises RAR-related-orphan-receptor-gamma-t (RORγt) in T-8 
helper-17 (Th17) cells, which, in turn, release their effector cytokines IL-17, IL-21 and IL-22 to initiate 9 
and amplify local autoimmune reactions and chronic inflammation.[2]  10 
Several drugs targeting the IL-23/IL-17 axis have been successfully tested in PsO and PsA.[2] For 11 
example, ustekinumab and secukinumab, inhibitors of IL-12/IL-23p40 and IL-17A respectively, are 12 
recommended as a second-line biologic treatment for PsA patients inadequate responders to 13 
conventional-synthetic (cs) Disease-Modifying-Anti-Rheumatic-Drugs (DMARDs) who had failed at 14 
least one Tumour-Necrosis-Factor (TNF) inhibitor (TNFi).[4,5] However, by blocking these pathways, 15 
while 47%-64% of patients achieve a 75%-improvement in skin disease [Psoriasis-Area-and-Severity-16 
Index (PASI75)], success in treating joints is more modest, and a mere 20% improvement [American-17 
College-of-Rheumatology (ACR20)] is observed in 35%-50% of patients.[6,7] The new IL-23p19 18 
selective inhibitors have been shown to be more effective, and ACR20 is reached in approximately 60% 19 
[8,9]. However, while a similar proportion of patients achieve almost complete psoriasis clearance 20 
(PASI90), high hurdles joint disease ACR50/ACR70 is achieved in only 33-36% and 13-20% of patients, 21 
respectively.[8,9]  22 
To date, the mechanism for such divergent skin-joint response, consistent across multiple trials, 23 
remains largely unexplained. We [2] and others [10] have postulated that different target expression 24 
levels in skin and joints contribute to the diverse clinical response. For example, Belasco et al. reported  25 
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that gene expression patterns in skin and synovium are distinct, showing a stronger IL-17 signature in 1 
skin than in synovium, and more equivalent TNF signal across both tissues [10]. Here we present new 2 
evidence exploring the expression of the IL-12/IL-23 axis in psoriatic skin versus matched synovial 3 
tissue at both molecular and protein level. 4 
METHODS	5 
Full methods are included in supplementary material. Briefly, 27 patients fulfilling the CASPAR criteria 6 
[11] with active peripheral joint disease despite csDMARDs and either biologic-naïve/ failing TNFi were 7 
recruited in this observational/open-label study (REC15/LO/0584). Patients underwent a baseline 8 
ultrasound-guided synovial biopsy [12] and lesional/non-lesional skin punch-biopsies, and were then 9 
treated with TNFi/ustekinumab as per local guidelines. The chosen primary endpoint was 16-weeks. 10 
Gene expression was analysed by real-time PCR (Fluidigm). Paraffin-embedded skin/synovium samples 11 
were stained with Haematoxylin-Eosin. Immune-cells/IL-23-axis were quantified by 12 
immunohistochemistry. Synovial tissue were categorised in “low-grade” (score 0-1) or “high-grade” 13 
(score 2-7) synovitis [13] and in pathotypes (lympho-myeloid/diffuse-myeloid/pauci-immune) [14]. 14 
RESULTS	15 
Patients’	characteristics	and	treatment	response	16 
Baseline and 16-weeks demographic and clinical features are summarized in Figure.1. The overall 17 
male-to-female ratio was ~1:1 (59% female), the average age was 45.4±12.5 and disease duration >10 18 
years. 78% of patients had concomitant skin involvement, with a mean PASI of 7.8. As per inclusion 19 
criteria, all patients had active joint disease [68-tender-joints-count 30.9±19.2, 66-swollen-joints-count 20 
13±10.4, Disease-Activity-Score-(DAS) 4.3±1.1] despite treatment with csDMARDs ± anti-TNF. 21 
Following the baseline biopsy, patients were treated with anti-TNF (n=18) if they were biologic-naïve 22 
or ustekinumab (n=9) if they had not responded to at least one TNFi. The higher number of females in 23 
the ustekinumab-arm (8/9) reflects the gender differences in TNFi-treatment outcomes observed in 24 
registries [15] (Figure.1A). At 16-weeks, ESR, tender-joint scores, Ritchie-Articular-Index (RAI), VAS-25 
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pain, Likert-physician-assessment and DAS were significantly higher in the ustekinumab-treated group; 1 
PASI-scores improved from baseline in both groups (-4.7±7.5 in TNFi-treated vs -8.9±14.3 in 2 
ustekinumab-treated) and were comparable between the two treatment arms (2.3±2.6 in TNFi-treated 3 
vs 2.3±2.3 in ustekinumab-treated) (Figure.1B). However, while significantly more patients in the anti-4 
TNF group achieved EULAR(DAS)-response compared with ustekinumab-treated patients (70.6% vs 5 
22.2%), there was a trend in favour of ustekinumab in terms of skin responses (Figure.1C). Besides, as 6 
joint-response to ustekinumab can be delayed up to 24-28 weeks, clinical responses were also assessed 7 
at 24-weeks. As shown in Supplementary Figure.S1, ustekinumab-treated patients maintained 8 
significantly higher tender joint scores, RAI, VAS-pain, Likert-physician-assessment and DAS-score; 50% 9 
and 68.8% of patients in the ustekinumab- and TNFi arms achieved EULAR(DAS)-response, respectively. 10 
Individual-patient joint/skin responses are summarized in Supplementary Table.S1.  11 
Gene	expression	profiles	in	paired	skin	and	synovium	reveal	tissue-specific	signatures	and	12 
divergent	expression	patterns		13 
Gene expression analysis was performed on 14 matched synovial tissue, lesional and adjacent non-14 
lesional skin. As shown in Figure.2A, principal component analysis (PCA), built on the expression of 80 15 
inflammation-related genes (Supplementary Table.S2), showed that the synovium clusters away from 16 
the skin, with a partial overlapping of lesional and non-lesional skin. To further investigate the gene 17 
variance contributing to the diversity of expression within each anatomic site (skin/synovium), related 18 
PCA plots were co-visualised with loading plots (biplots) (Figure.2B and C). IL17A/F, IL23R and IL21 19 
were the major contributors of PC1/2 variation in lesional skin. In synovium, genes related to Ectopic-20 
Lymphoid-Structure (ELS) formation (CXCL13, CXCR5) and the IL-23 axis (IL23A, IL12B, IL23R) together 21 
strongly contributed to the PC variation. For instance, CXCR5 and IL23A robustly aligned with PC1 in 22 
accounting for 35.4% of the variance within the synovium data set and CXCL13 strongly and equally 23 
contributed to PC1 and PC2 variation. We next assessed the relative gene expression of the drug-24 
targets of TNF- and IL-23/IL-12-inhibitors, i.e. TNF, IL23A (encoding IL-23p19), IL12B (encoding IL-25 
23p40) and IL23R (Figure.2D). TNF was generally homogeneously expressed in both skin and synovial 26 
 6 
tissue. Conversely, IL23A, IL12B and IL23R showed higher expression in lesional skin compared to both 1 
non-lesional skin and synovium. Interestingly, we observed that while some patients did express IL-23 2 
cytokines/receptor in both skin and joint, others had discordant expression, i.e. active IL-23 pathway 3 
in the lesional skin but not in the synovium. To investigate potential mechanisms for the diverse 4 
expression of the IL-23-axis within the synovium, we stratified patients based on the degree of synovial 5 
inflammation.[13] Both IL12B and IL23R genes, but not IL23A, were significantly more expressed in 6 
patients with higher synovitis scores (Figure.2E). Notably, despite the major variance in the degree of 7 
synovial inflammation and histological pathotypes, there were no significant clinical differences in the 8 
two patient-groups (Supplementary-Table.S3 and S4). 9 
Synovial	 IL-23p40/p19	 and	 IL-23R	 protein	 expression	 correlates	 with	 the	 histological	10 
inflammatory	status		11 
To confirm the molecular findings, we next evaluated protein expression levels of IL-23p40, IL-23p19 12 
and IL-23R in skin and synovium by immunohistochemistry. As expected, the percentage of IL-23p40-, 13 
IL-23p19- and IL-23R-positive cells was significantly higher in lesional skin compared to paired non-14 
lesional skin (Figure.3A and B); within the synovium, it was greater in patients with higher degree of 15 
inflammation (Figure.3C and D) and in lympho- and diffuse-myeloid pathotypes (Supplementary 16 
Figure.S2). This result was in line with the positive correlation observed between the synovial 17 
inflammatory score and the proportion of IL-23p40/IL-23p19/IL-23R-positive cells (Figure 3E), as well 18 
as their correlation with each other’s (data not shown). Of note, the percentage of IL-23p40/IL-19 
23p19/IL-23R-positive cells at baseline was, on average, comparable between the treatment groups 20 
despite different drug-exposure (Supplementary Table.S5). Except for the LIKERT-patient-score, we 21 
did not detect other significant correlations between IL-23-axis expression and clinical parameters at 22 
baseline, suggesting that patients with comparable disease severity may have, in fact, heterogeneous 23 
histopathological features and expression of drug-targets within the diseased synovium 24 
(Supplementary Table.S6).  25 
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To further assess whether the IL-23-axis heterogeneity tracks across different stages of the disease, 1 
we analysed IL-23 expression pattern in the synovium of 21 treatment-naïve PsA patients with <12 2 
months symptoms. As shown in Supplementary Figure.S3, overall, there was a positive correlation 3 
between IL-23p40/IL-23p19/IL-23R-positive cells and synovitis scores, and lower IL-23 4 
cytokines/receptor tissue-availability in the pauci-immune compared to macrophage-rich pathotypes. 5 
Similarly to established PsA, we did not find significant correlations between clinical parameters and 6 
IL-23 axis expression. Finally, to investigate whether the differential IL-23-expression observed in PsA 7 
synovium was disease-specific or related to synovial histopathology, we quantified IL-23p40/IL-8 
23p19/IL-23R in a cohort of 17 treatment-naïve rheumatoid arthritis (RA) patients spanning diverse 9 
degrees of synovial inflammation and histopathotypes, and confirmed that, at least in the early phases 10 
of RA, IL-23 expression pattern is pathology-related and significantly associates with the presence of 11 
ELS (Supplementary Figure.S4). 12 
DISCUSSION	13 
To our knowledge, this study provides first-time detailed evidence of the expression of the IL-23 axis 14 
(IL-23p40/ IL-23p40p19/IL-23R), both at transcript and protein level, in matched skin-synovium 15 
obtained from clinically active PsA patients before undergoing anti-TNF or ustekinumab.  16 
Using a PCR-Fluidigm-assay of 80 inflammation-related genes, first, we demonstrated distinct synovial 17 
gene expression clustering away from paired skin but a partial overlapping between lesional and non-18 
lesional skin profiles. We also showed that IL-17 and IL-23 cytokines together with CXCL13/CXCR5, key 19 
chemokines involved in ELS formation, significantly contribute to the gene expression variance within 20 
skin and joint sites, respectively. These results are in line with those reported by Belasco et al. [10] 21 
demonstrating that IL-17 is a major contributor of the gene expression variability within the lesional 22 
skin, and Celis et al. [16] who showed that in synovial biopsies (unmatched for skin samples) the 23 
expression of IL-23 correlates with ELS-positive samples.  24 
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The analysis of the expression profiles of biologic-DMARDs-targets demonstrated that TNF was more 1 
homogeneously expressed in skin and synovial tissue, while IL23A/IL12B/IL23R were generally higher-2 
expressed in lesional skin compared to both non-lesional skin and synovium. The synovial expression 3 
of IL23A/IL12B/IL23R was, in fact, greatly heterogeneous and could be either similar to or much lower 4 
than the paired lesional skin. Notably, IL12B and IL23R transcripts levels were dependent on the degree 5 
of tissue inflammation, being more expressed in the presence of higher synovitis scores. Similarly, we 6 
confirmed a preferential expression of IL-23p40/IL-23p19/IL-23R proteins in patients with high-grade 7 
synovitis and immune-cells-rich histopathotypes. Importantly, patients with variable degrees of 8 
synovial inflammation and diverse pathotypes, as well as different levels of IL-23-cytokines/receptor 9 
could not be phenotypically distinguished by conventional clinical scores. Furthermore, despite 10 
variable drug-exposure, the pathology of the IL-23 axis in active patients was comparable at baseline. 11 
We confirmed that IL-23-axis expression relates to the synovial histopathology not only in PsA at 12 
different stages of the disease, including early treatment-naïve patients, but also in the early phase of 13 
RA, investigated as disease control. Therefore, the pattern of expression of the IL-23 axis does not 14 
seem to be disease-specific but rather dependent on the inflammatory status and histological features 15 
of the synovial tissue in both PsA and RA.  16 
While it is generally accepted that patients with high disease activity respond better to biologics, 17 
clinimetric measures cannot determine the grade of histological synovitis or drug-target expression 18 
levels. Tissue bioavailability of the “target”, of course, does not guarantee clinical response; however, 19 
there is evidence to suggest that, for example, TNF levels in RA synovium are associated with better 20 
response to TNFi, [17] and other specific synovial tissue signatures are linked with different outcomes 21 
to anti-TNF [18] and anti-IL-6R therapy.[19] The results reported here support the concept that 22 
heterogeneous drug-target bioavailability in the diseased tissue might also apply to the IL-23 axis. This 23 
prompted the hypothesis that different joint response rates in PsA, often divergent from the skin-24 
response, might be explained, at least partially, by the preferential expression of the IL-23-axis by 25 
subsets of patients with higher histological synovitis but not necessarily higher disease activity.  26 
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PsABRE was an exploratory study, not designed to assess efficacy; thus, the relatively small sample-1 
size in each treatment-arm did not allow to test the above hypothesis. Moreover, no direct 2 
comparisons could be carried out between the anti-TNF- and the ustekinumab-treated cohorts: both 3 
populations failed to respond to csDMARDs, but whilst the former was biologic-naïve, the latter had 4 
inadequately responded to at least one TNFi representing, therefore, a more difficult-to-treat group. 5 
The trial took place in a real-life setting with no external or industry support; hence, the recruitment 6 
and treatment allocation had to follow the UK National Institute for health and Care Excellence (NICE) 7 
prescription-guidelines with consequent different drug-exposure in the two groups. Despite these 8 
limitations, the main value of the study resides in its molecular pathology characterization of paired 9 
skin and US-guided synovial biopsies of the most inflamed joint, including small joints, that 10 
demonstrates a divergent profile between the two diseased tissues and, generally, a lower level of 11 
expression of the IL-23 axis in the synovial tissue particularly in patients with low-grade synovitis.  12 
The heterogenous synovial expression of the IL-23-axis provides a plausible mechanistic explanation 13 
for the divergent outcomes consistently observed in clinical trials whereby IL-23i have better results in 14 
PsA skin than in joints. This hypothesis needs to be tested in larger, appropriately designed and 15 
powered studies. Identifying biomarkers of joint-response to therapy in patients clinically 16 
indistinguishable is going to be vital to refine PsA clinical classification and enrich for treatment 17 
response while reducing unnecessary exposure to costly and potentially toxic medications. 18 
KEY	MESSAGES		19 
What	is	already	known	about	this	subject?		20 
• PsA is a chronic heterogeneous inflammatory condition affecting patients with psoriasis, and the IL-21 
23/IL-17 axis is believed to be key in psoriasis and PsA pathogenesis. 22 
• Several drugs targeting the IL-23/IL-17 axis have been successfully tested in the context of psoriasis 23 
and PsA but, while 50-60% of patients achieve almost complete psoriasis clearance upon treatment, 24 
 10 
the joint disease improvement is modest. To date, the mechanism for the divergent skin-joint response 1 
remains largely unexplained.  2 
What	does	this	study	add?	3 
• It provides first-time detailed evidence of the expression of the IL-23 axis in matched skin and synovial 4 
tissue from active PsA patients demonstrating distinct gene expression clustering of the synovium 5 
away from paired skin. It reveals that, while IL23A, IL12B and IL23R are expressed at a high level in 6 
lesional skin, their expression in the synovium is hugely heterogeneous.  7 
• It demonstrates that, while patients with diverse degrees of synovial inflammation could not be 8 
distinguished clinically by conventional clinimetric measures, the IL-23 axis signature is differentially 9 
expressed within the synovial tissue and strongly linked to high-grade synovitis.	10 
How	might	this	impact	on	clinical	practice	or	future	developments?	11 
• This study demonstrates that PsA synovial tissue shows a heterogeneous IL-23 axis profile 12 
independently of its expression in paired-skin samples, thus providing a plausible mechanistic 13 
explanation for the divergent skin and joint clinical response to IL-23 inhibitors. It supports the need 14 
to test in larger appropriately designed and powered studies whether drug-target bioavailability 15 
correlates with the likelihood of response. Identifying biomarkers of joint-response to therapy in 16 
patients clinically indistinguishable is going to be vital to improve disease outcomes, prevent disability 17 
and reduce healthcare and societal costs. 18 
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FIGURE	CAPTIONS	1 
Figure 1 Baseline and 16-weeks characteristics of the patients included in the Psoriatic Arthritis 2 
Pathobiology and its Relationship with Clinical Disease Activity (PsABRE) study. A, Baseline features 3 
of the whole cohort (n=27) and comparison of variables between patients receiving anti-TNF (n=18) or 4 
ustekinumab (n=9). B, Patients’ characteristics at the chosen primary endpoint, i.e. 16-weeks post-5 
treatment (n=26, one patient lost to follow-up) and comparison between TNFi- (n=17) and 6 
ustekinumab-treated patients (n=9). A-B, p-values calculated using Mann–Whitney U-test or Fisher’s 7 
exact test as required (TNFi-arm vs ustekinumab-arm). C, Skin (PASI50) and joints [EULAR(DAS) 8 
good/moderate vs none] response at 16-weeks. p-values calculated using Fisher’s exact test. SD, 9 
Standard Deviation; n, number; ESR, erythrocyte sedimentation rate; CRP, C-Reactive Protein; TJC, 10 
Tender Joints Count; SJC, Swollen Joints Count; RAI, Ritchie Articular Index; PASI, Psoriasis Area and 11 
Severity Index; VAS, Visual Analogue Scale (0-100); GH, Global Health; DAS, Disease Activity Score; 12 
HAQ, Health Assessment Questionnaire; TNF, Tumour Necrosis Factor; DMARDs, Disease Modifying 13 
Anti-Rheumatic Drugs; ns, non-significant; EULAR, European League Against Rheumatism. 14 
Figure 2 Gene expression analysis in matched skin and synovium from PsA patients. A, Principal 15 
component (PC) analysis performed on the expression data of a set of 80 selected genes in 14 matched 16 
non-lesional (non les.) and lesional skin and synovium. The first two eigenvalues were plotted with 17 
data ellipses for each tissue type using a confidence interval of 0.95. The PCA clearly separates 18 
synovium (blue dots) from non-lesional skin (non les., green dots) and lesional skin (red dots). B-C, 19 
Biplots showing individuals repartition in PC1 and 2 (black dots) and loading plots assessing the 20 
contribution of each of the 80 genes analysed in the PC, displayed for the lesional skin (B) and synovial 21 
tissues (C). Genes names are indicated if their contribution to the PC variance is >1. D, Heatmap 22 
representing TNF, IL12B (IL-23p40 protein), IL23A (IL-23p19 protein) and IL23R expression in 14 23 
matched non-lesional (non les.) and lesional skin and synovium samples. dd-threshold cycle (ddCT) are 24 
shown in colorimetric scale (low expression in blue, high expression in red). Lines 1 to 11 represent 25 
anti-TNF-treated patients, lines 12 to 14 ustekinumab-treated patients. E, IL12B, IL23A and IL23R gene 26 
 15 
expression in synovial biopsies classified as “low” (0-1) and “high” (2-7) synovial inflammatory score 1 
(Krenn’s score). p-values were calculated using Mann–Whitney U-test, * = p < 0.05, mean and standard 2 
deviation are shown. 3 
Figure 3 Expression of IL-23p40, IL-23p19 and IL-23R in skin and synovium from PsA patients. A and 4 
C, Representative images of sections of PsA non-lesional (non les.) and lesional skin (A), and synovial 5 
tissue of different degree of inflammatory scores (C) immuno-stained for IL-23p40, IL-23p19 and IL-6 
23R. Scale bar = 200μm. Enlarged images correspond to the respective boxed areas. B and D, Digital 7 
image analysis was performed on non-lesional and lesional skin (B) (n=11-12) and synovium (D) (low 8 
inflammatory score, n=4-8; high inflammatory score, n=13-14) sections. IL-23p40, IL23p19 and IL23R 9 
positive cells were determined using QuPath software and are presented as % of the total number of 10 
cells. Results are shown as mean ± standard deviation. * = p < 0.05, **= p < 0.01 as assessed by Mann–11 
Whitney U-test. E, Correlations between inflammatory scores and IL-23p40, IL-23p19 or IL-23R 12 
percentages of positive cells within the synovial tissue. p-values, calculated by Spearman’s bivariate 13 
correlation analysis, are indicated on each graph. 14 
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Female % (n) 59% (16) 44.4% (8) 88.9% (8) p=0.03
Age years (mean ± SD) 45.4 ± 12.5 42.2 ± 11.2 51.8 ± 12.9 ns
Disease duration years 
(mean ± SD)
10.2 ± 11.8 7.3 ± 7.2 15.3 ± 16.6 ns
ESR mm/hr (mean ± SD) 24 ± 16.7 22.8 ± 15.4 26.3 ± 19.8 ns
CRP mg/l mean (mean ± SD) 11.5 ± 21.1 11.4 ± 22.7 11.7 ± 18.6 ns
TJC/78 (mean ± SD) 34.2 ± 22.6 31 ± 25.1 40.7 ± 15.9 ns
TJC/68 (mean ± SD) 30.9 ± 19.2 27.7 ± 21.2 37.2 ± 13.1 ns
RAI (mean ± SD) 18.7 ± 9.8 16.6 ± 10.7 23.1 ± 5.9 ns
SJC/76 (mean ± SD) 13.6 ± 10.8 11.6 ± 8.5 17.7 ± 13.9 ns
SJC/66 (mean ± SD) 13 ± 10.4 11.3 ± 8.6 16.3 ± 13.1 ns
SJC/44 (mean ± SD) 10.3 ± 8.3 9.2 ± 7.8 12.6 ± 9.3 ns
Skin involvment, yes % (n) 78% (21) 83,3% (15) 66.7% (6) ns
PASI (mean ± SD) 7.8 ± 10.7 6.5 ± 8.1 11 ± 16 ns
VAS tiredness (mean ± SD) 60 ± 30.2 59.1 ± 30.4 61.8 ± 31.6 ns
VAS pain (mean ± SD) 70.6 ± 21.7 70.3 ± 17.1 71.2 ± 30.2 ns
VAS GH Patient (mean ± SD) 70 ± 25.1 72.3 ± 20.8 65.4 ± 33.1 ns
VAS GH Physician (mean ± SD) 62.2 ± 16.2 61.2 ± 16.4 64.2 ± 16.5 ns
LIKERT Patient (mean ± SD) 3.8 ± 0.8 3.8 ± 0.8 3.9 ± 0.9 ns
LIKERT Physician (mean ± SD) 3.6 ± 0.6 3.4 ± 0.6 3.8 ± 0.7 ns
DAS (mean ± SD) 4.3 ± 1.1 4.1 ± 1.2 4.8 ± 1 ns
HAQ (mean ± SD) 1.9 ± 0.6 1.8 ± 0.6 2.1 ± 0.5 ns
Previous anti-TNF, yes % (n) 33.3% (9) 0% (0) 100% (9) p<0.0001
Current DMARDs, yes % (n) 70.4% (19) 66.7% (12) 77.8% (7) ns
TOTAL POPULATION
(26 PATIENTS)
ANTI-TNF 
(17 PATIENTS)
USTEKINUMAB 
(9 PATIENTS) p-values
1
6
 W
E
E
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S
ESR mm/hr (mean ± SD) 17.6 ± 14.6 12.2 ± 8.8 27.7 ± 18.4 p=0.05
CRP mg/l mean (mean ± SD) 6.3 ± 8.7 4.2 ± 6.7 10.4 ± 10.8 ns
TJC/78 (mean ± SD) 25.7 ± 22.1 28.2 ± 20.9 39.7 ± 17.9 p=0.01
TJC/68 (mean ± SD) 23.3 ± 19.5 16.1 ± 18.0 36.8 ± 15.0 p=0.007
RAI (mean ± SD) 13.9 ± 10.6 10.9 ± 11.1 19.4 ± 7.2 p=0.02
SJC/76 (mean ± SD) 8.3 ± 9.3 7.4 ± 8.0 10.1 ± 11.8 ns
SJC/66 (mean ± SD) 7.8 ± 9.0 7.0 ± 8.0 9.4 ± 11.0 ns
SJC/44 (mean ± SD) 5.8 ± 6.2 5.6 ± 6.0 6.3 ± 6.9 ns
PASI (mean ± SD) 2.2 ± 2.5 2.3 ± 2.6 2.3 ± 2.3 ns
VAS tiredness (mean ± SD) 54 ± 31.6 50.1 ± 31.9 61.3 ± 31.6 ns
VAS pain (mean ± SD) 46.7 ± 32.2 37.2 ± 30.2 64.6 ± 29.4 p=0.05
VAS GH Patient (mean ± SD) 50.2 ± 33.4 46.5 ± 33.9 57.1 ± 33.3 ns
VAS GH Physician (mean ± SD) 45.0 ± 26.0 38.8 ± 24.3 56.7 ± 26.1 ns
LIKERT Patient (mean ± SD) 2.9 ± 1.1 2.8 ± 1.1 3.1 ± 1.2 ns
LIKERT Physician (mean ± SD) 2.9 ± 1.3 2.5 ± 1.2 3.8 ± 1.1 p=0.01
DAS (mean ± SD) 3.4 ± 1.4 3.0 ± 1.5 4.1 ± 0.9 p=0.03
HAQ (mean ± SD) 1.5 ± 0.9 1.2 ± 1.0 2.0 ± 0.7 ns
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SUPPLEMENTARY	METHODS	1 
	2 
Patients		3 
Twenty-seven (27) patients fulfilling the ClASsification for Psoriatic ARthritis (CASPAR) criteria [11] with 4 
active peripheral joint disease ( ³3 tender and ³3 swollen joints) despite an adequate trial of at least 5 
two csDMARDs and either biologic-naïve or failing one or more TNFa-inhibitor (TNFi) were recruited 6 
to this observational/open-label real-life study Psoriatic Arthritis PathoBiology and its Relationship 7 
with Clinical DiseasE Activity (PsABRE) at Bart’s Health NHS Trust. All patients underwent a baseline 8 
ultrasound (US)-guided needle synovial biopsy of the most inflamed peripheral joint, including small 9 
joints, as previously described.[12] Lesional and adjacent non-lesional skin punch biopsies were 10 
collected from patients with active skin disease at baseline. According to the National Institute for 11 
Health and Care Excellence (NICE UK) prescribing guidelines, patients biologic-naïve were treated with 12 
TNFi while patients who had already failed one or more anti-TNF agents received ustekinumab. The 13 
chosen primary endpoint was 16-weeks. Clinical and response data were also collected at 24-weeks in 14 
view of the delayed response to ustekinumab. Summary of treatments and associated EULAR/PASI50 15 
responses at 16 and 24-weeks are presented in Supplementary Table.S1. Synovial/skin biopsy samples 16 
were partly stored in RNA-later and partly fixed in formalin. All patients gave written informed consent 17 
prior to recruitment. The study was approved by the local ethics committee (REC 15/LO/0584). 18 
To validate the relationship between the IL-23-axis expression and the synovial histopathology, 21 19 
psoriatic arthritis and 17 rheumatoid arthritis patients part of the Pathobiology of Early Arthritis Cohort 20 
(05/Q070/198) were also analysed. All patients had <12 months duration of symptoms and were 21 
treatment-naïve when underwent US-guided synovial biopsy.    22 
 23 
Patient	and	Public	Involvement	statement	24 
No funding or time were specifically allocated to patient and public involvement (PPI) in the original 25 
application. However, a patients’ survey was conducted at the time of the trial to ensure patients were 26 
satisfied with the care received as part of the research study and to receive feedback to improve the 27 
delivery of the study.  28 
	29 
Gene	expression	analysis	30 
Total RNA was extracted from synovium and skin using a Trizol/Chloroform method as previously 31 
described.[14] The relative expression of 80 genes relevant to inflammatory pathways, including genes 32 
encoding IL-23-cytokines/receptor, was quantified by real-time PCR using Fluidigm technology 33 
(Fluidigm corporation, San Francisco, CA-USA) (Supplementary Table.S2). Data were analysed with a 34 
 21 
ΔΔCt method using beta-glucuronidase (GUSB) as the housekeeping gene and a mix of cDNA from 3 1 
synovial-tissue samples as reference.  2 
	3 
Histology,	immunohistochemistry	and	image	analysis	4 
Skin specimens (lesional/non-lesional) and a minimum of 6 synovial-tissue fragments were paraffin-5 
embedded and sectioned at 3µm. Synovial samples were stained with Haematoxylin and Eosin (H&E), 6 
and the presence/degree of synovitis was quantified based on parameters previously published [13] 7 
by two independent observers; samples were defined as “low-grade synovitis” if score 0-1 or “high-8 
grade synovitis” if score 2-7. Moreover, as previously described in RA synovial tissue [14], synovial 9 
tissue sections were immuno-stained for CD3, CD20, CD68 and CD138 in order to quantify the immune 10 
infiltrate of T-cells, B-cells, macrophages and plasma cells, respectively. Based on a combination of 11 
semi-quantitative score [14], patients were categorised in histological pathotypes (lympho-myeloid, 12 
diffuse-myeloid and fibroid/pauci-immune) as previously described [14]. To assess the presence and 13 
distribution of IL-23-related cytokines and receptors-(R), both synovial and skin specimens were 14 
immuno-stained for IL-23p40 (Novus Biologicals, Centennial, CO-USA), IL-23p19 (BioLegend, San Diego, 15 
CA-USA) and IL-23R (Novus Biologicals). Matching isotype antibodies were used as controls. IL-23R cell 16 
specificity has also been tested by double immunofluorescence staining with CD3, CD68 and CD20 17 
(data not shown). Slides were counterstained with Haematoxylin and mounted with DPX mounting 18 
medium (Sigma-Aldrich, Saint-Louis, MO-USA). All sections were scanned using the digital slide scanner 19 
Nanozoomer S210 (Hamamatsu Photonics, Japan). The percentage of positive cells was determined by 20 
quantitative digital image analyses using QuPath software.[20]  21 
	22 
Statistical	analysis	23 
Differences in continuous variables were analysed by Mann–Whitney U-test (two groups) or Kruskal–24 
Wallis with Dunn's post-test (multiple groups). Fisher's exact test was used to evaluate significant 25 
associations between categorical variables. Correlations were analysed by Spearman’s correlation test. 26 
Statistical analyses were performed using GraphPad-Prism-v8-software, p-values<0.05 were 27 
considered significant. The PCA and biplots were created using function prcomp from the stats package 28 
within R statistics (version 3.5.3) and factoextra R package.[21] The first two eigenvalues were plotted 29 
with data ellipses for each tissue type using a confidence interval of 0.95. 30 
  31 
 22 
 1 
 2 
Figure S1 24-weeks characteristics of the patients included in the Psoriatic Arthritis Pathobiology and 3 
its Relationship with Clinical Disease Activity (PsABRE) study. A, Patients’ characteristics at 24-weeks 4 
post-treatment (n=24, three patients lost to follow-up) and comparison between TNFi- (n=16) and 5 
ustekinumab-treated patients (n=8). p-values calculated using Mann–Whitney U-test or Fisher’s exact 6 
test as required (TNFi-arm vs ustekinumab-arm). B, Skin (PASI50) and joints [EULAR(DAS) 7 
good/moderate vs none] response at 24-weeks. p-values calculated using Fisher’s exact test.  8 
SD, Standard Deviation; n, number; ESR, erythrocyte sedimentation rate; CRP, C-Reactive Protein; TJC, 9 
Tender Joints Count; SJC, Swollen Joints Count; RAI, Ritchie Articular Index; PASI, Psoriasis Area and 10 
Severity Index; VAS, Visual Analogue Scale (0-100); GH, Global Health; DAS, Disease Activity Score; TNF, 11 
Tumour Necrosis Factor; DMARDs, Disease Modifying Anti-Rheumatic Drugs; ns, non-significant; 12 
EULAR, European League Against Rheumatism. 13 
  14 
 23 
 1 
 2 
Table S1 Summary of patients’ treatment distribution (anti-TNF or ustekinumab), and individual joint 3 
[EULAR(DAS) good/moderate versus none] and skin (PASI50) responses. 4 
0, non-responder; 1, responder; LtFU, Lost to Follow-Up; N/A, Not Applicable; TNF, Tumour Necrosis 5 
Factor; EULAR, European League Against Rheumatism; PASI, Psoriasis Area and Severity Index. 6 
 7 
  8 
 24 
 1 
Table S2 List of TaqMan probes used for gene expression analysis by real-time polymerase chain 2 
reaction (PCR) with Fluidigm technology (Fluidigm corporation, San Francisco, CA-USA). 3 
  4 
 25 
 1 
 2 
Table S3 Baseline clinical variables comparison between patients characterized by a lower (n=9) or 3 
higher (n=15) synovial inflammatory score [13]. 24/27 baseline synovial tissues were included in the 4 
analysis; 3 samples were classified as “ungraded” (absence of lining layer and/or necrotic tissue and/or 5 
absent of macrophages in the sublining). p-values were calculated using Mann–Whitney U-test or 6 
Fisher's exact test as appropriate.  7 
SD, Standard Deviation; n, number; ESR, erythrocyte sedimentation rate; CRP, C-Reactive Protein; TJC, 8 
Tender Joints Count; SJC, Swollen Joints Count; RAI, Ritchie Articular Index; PASI, Psoriasis Area and 9 
Severity Index; VAS, Visual Analogue Scale (0-100); GH, Global Health; DAS, Disease Activity Score; HAQ, 10 
Health Assessment Questionnaire; TNF, Tumour Necrosis Factor;  DMARDs, Disease Modifying Anti-11 
Rheumatic Drugs; ns, non-significant. 12 
 13 
  14 
 26 
 1 
Table S4 Baseline clinical variables comparison between patients characterized by a lympho-myeloid 2 
(n=3), diffuse-myeloid (n=11) or pauci-immune (n=10) pathotype as previously defined in rheumatoid 3 
arthritis [14]. Briefly, immune-cells infiltrate was defined by immunohistochemistry (CD3 for T-cells, 4 
CD20 for B-cells, CD68 for macrophages and CD138 for plasma cells) and quantified using a semi-5 
quantitative score (0-4) [14]. Accordingly, patients were categorised as lympho-myeloid if CD20 score 6 
≥2 and/or CD138 score >2, diffuse-myeloid if CD68 sublining score ≥2, CD20 score ≤1 and CD138 score 7 
≤2, and pauci-immune if CD68 sublining score <2 and CD3/CD20/CD138 score <1. 24/27 baseline 8 
synovial tissues were included in the analysis; 3 samples were classified as “ungraded” (absence of 9 
lining layer and/or necrotic tissue and/or absent of macrophages in the sublining). p-values were 10 
calculated using Kruskal Wallis or Fisher's exact test as appropriate.  11 
SD, Standard Deviation; n, number; ESR, erythrocyte sedimentation rate; CRP, C-Reactive Protein; TJC, 12 
Tender Joints Count; SJC, Swollen Joints Count; RAI, Ritchie Articular Index; PASI, Psoriasis Area and 13 
Severity Index; VAS, Visual Analogue Scale (0-100); GH, Global Health; DAS, Disease Activity Score; HAQ, 14 
Health Assessment Questionnaire; TNF, Tumour Necrosis Factor;  DMARDs, Disease Modifying Anti-15 
Rheumatic Drugs; ns, non-significant. 16 
  17 
 27 
 1 
Figure S2 A, Distribution of the % of IL-23p40-, IL-23p19- and IL-23R-positive cells (of the total number 2 
of cells) according to the histological pathotypes at baseline. B, Distribution of the % of IL-23p40-, IL-3 
23p19- and IL-23R-positive surface (of the total area) according to the histological pathotypes at 4 
baseline. L = Lympho-myeloid (n=3), M= diffuse-Myeloid (n=9-10), P= Pauci-immune (n=5-9). Results 5 
are presented as mean ± standard deviation. *p < 0.05, **p < 0.01 as assessed by Kruskal–Wallis with 6 
Dunn’s post-test. 7 
  8 
 28 
 1 
 2 
Table S5 IL-23p19, IL-23p40 and IL-23R baseline synovial protein expression levels stratified according 3 
to the biologic DMARD received afterwards (anti-TNF or ustekinumab). IL-23p19, IL-23p40 and IL-23R 4 
were detected by immunohistochemistry and quantified by Digital Image Analysis. Mean ± Standard 5 
Deviation of % of positive cells are represented. Anti-TNF: n=14-16; ustekinumab: n = 5-6. 6 
  7 
 29 
 1 
 2 
 3 
 4 
Table S6 Correlations between IL-23p40/IL-23p19/IL-23R protein expression (as percentage of positive 5 
cells assessed by IHC) and baseline clinical variables. p-values were calculated using Spearman r test. 6 
*p < 0.05, **p < 0.01 7 
ESR, erythrocyte sedimentation rate; CRP, C-Reactive Protein; TJC, Tender Joints Count; SJC, Swollen 8 
Joints Count; RAI, Ritchie Articular Index; PASI, Psoriasis Area and Severity Index; VAS, Visual Analogue 9 
Scale (0-100); GH, Global Health; DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; 10 
TNF, Tumour Necrosis Factor;  DMARDs, Disease Modifying Anti-Rheumatic Drugs; ns, non-significant. 11 
  12 
 30 
 1 
Figure S3 IL-23 cytokines and receptor expression in early Psoriatic Arthritis. A, Demographic and 2 
clinical features of the early PsA cohort (n=21); B, Correlations between inflammatory scores and IL-3 
23p40, IL-23p19 or IL-23R percentages of positive cells within the synovial tissue. p-values, calculated 4 
by Spearman’s bivariate correlation analysis, are shown on each graph. C, Distribution of the % of IL-5 
23p40-, IL-23p19- and IL-23R-positive cells (of the total number of cells) according to the histological 6 
pathotypes at baseline. L = Lympho-myeloid (n=4), M= diffuse-Myeloid (n=7-10), P= Pauci-immune 7 
 31 
(n=6-7). Results are presented as mean ± standard deviation. *p < 0.05 as assessed by Kruskal–Wallis 1 
with Dunn’s post-test. D, Correlations between IL-23p40/IL-23p19/IL-23R protein expression (as 2 
percentage of positive cells assessed by IHC) and baseline clinical variables. p-values were calculated 3 
using Spearman r test. SD, Standard Deviation; n, number; ESR, erythrocyte sedimentation rate; CRP, 4 
C-Reactive Protein; TJC, Tender Joints Count; SJC, Swollen Joints Count; VAS, Visual Analogue Scale (0-5 
100); GH, Global Health; DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; ns, non-6 
significant. 7 
  8 
 32 
 1 
Figure S4 IL-23 cytokines and receptor expression in early Rheumatoid Arthritis. A, Demographic and 2 
clinical features of the early arthritis RA cohort (n=17); B, Correlations between inflammatory scores 3 
and IL-23p40, IL-23p19 or IL-23R percentages of positive cells within the synovial tissue. p-values, 4 
calculated by Spearman’s bivariate correlation analysis, are shown on each graph. C, Distribution of 5 
the % of IL-23p40-, IL-23p19- and IL-23R-positive cells (of the total number of cells) according to the 6 
histological pathotypes at baseline. L = Lympho-myeloid (n=6), M= diffuse-Myeloid (n=6), P= Pauci-7 
immune (n=5). Results are presented as mean ± standard deviation. *p < 0.05, **p < 0.01 as assessed 8 
 33 
by Kruskal–Wallis with Dunn’s post-test. D, Correlations between IL-23p40/IL-23p19/IL-23R protein 1 
expression (as percentage of positive cells assessed by IHC) and baseline clinical variables. *p < 0.05, 2 
p-values were calculated using Spearman r test. SD, Standard Deviation; n, number; ESR, erythrocyte 3 
sedimentation rate; CRP, C-Reactive Protein; TJC, Tender Joints Count; SJC, Swollen Joints Count; VAS, 4 
Visual Analogue Scale (0-100); GH, Global Health; DAS, Disease Activity Score; HAQ, Health Assessment 5 
Questionnaire; ns, non-significant. 6 
